NCT06596616
Gadopiclenol vs Gadoxetate MRI for Liver Lesions
Enrolling by Invitation
Not specifiedAges 18–89ObservationalIcahn School of Medicine at Mount SinaiInvestigator-initiated
~23 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:RadiologyGadopiclenol
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Lesion Detection
Measured over End of study, at 6 months
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Sara Lewis, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
Acute renal insufficiency.
Severe chronic renal insufficiency (GFR \<30 mL/min/1.73 m2).
Age \<18y.
Unable or unwilling to give informed consent.
Contraindications for MRI (such as pacemakers, infusion pumps, pregnancy, allergy or previous adverse reactions to gadolinium contrast agents, severe claustrophobia).
What this trial measures
- Lesion DetectionEnd of study, at 6 months
Lesion detection (for any enhancing lesions including benign and malignant lesions, excluding cysts and completely necrotic treated malignant lesions) will be evaluated both for gadopiclenol-enhanced study (including unenhanced sequences from index MRI) and gadoxetate-enhanced MRI (the reference standard method): will be classified for each post- contrast phase as 0: no visible enhancing lesion, 1: visible enhancing lesion.